Montreal Researchers Join Global Trial for Potential Alzheimer’s Prevention Drug
Montreal researchers have entered a global trial testing a drug that may delay Alzheimer’s symptoms in biomarker‑positive, asymptomatic individuals. The study aims to assess the drug’s ability to prevent symptom development, amid ongoing international research for preventive therapies.
GMNA Montreal
Montreal researchers are participating in an international clinical trial that evaluates a drug intended to postpone the onset of Alzheimer’s symptoms in individuals who show biological markers but have not yet experienced cognitive decline.
The trial seeks to determine whether the drug can keep Alzheimer’s disease from developing symptoms in at‑risk people, a focus that reflects worldwide efforts to find preventive treatments for a disease that currently has no cure.
